<DOC>
	<DOCNO>NCT00382811</DOCNO>
	<brief_summary>The purpose project see weekly carboplatin compare phenoxodiol combination weekly carboplatin , effective late stage ovarian cancer see , , side-effects treatment may result .</brief_summary>
	<brief_title>OVATURE ( OVArian TUmor REsponse ) A Phase III Study Weekly Carboplatin With Without Phenoxodiol Patients With Platinum-Resistant , Recurrent Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologicallyconfirmed ovarian , fallopian , primary peritoneal carcinoma epithelial origin Recurrent persistent advance disease Have measurable disease Undergone least two course therapy platinum drug ( cisplatin carboplatin ) respond first course therapy determine either Response Evaluation Criteria Solid Tumors ( RECIST ) Gynecologic Cancer Intergroup ( GCIG ) criterion Disease relapse determine either RECIST GCIG criterion within 6 month completion second great course platinum therapy use 2 , 3 4weekly regimen platinumfree interval great 6 month time enrollment , time take last day platinum therapy Any number previous course platinum therapy nonplatinum therapy Likely survive least 3 month Karnofsky performance score least 60 % Have adequate physiological function without evidence major organ dysfunction evidence : serum creatinine &lt; 1.5 mg/dl serum transaminase level â‰¤ 3 x upper limit normal ( ULN ) reference laboratory bilirubin level &lt; ULN Have adequate hematological function define : platelet &gt; 100,000/mm3 white cell count ( WCC ) &gt; 3,000/mm3 neutrophil &gt; 1,500/mm3 hemoglobin &gt; 8.0 g/dl Aged &gt; 18 Be able understand risk benefit study give write informed consent participation . Patients mucinous histological type ovarian cancer Patients fail show clinical response ( RECIST GCIG criterion ) least one prior course platinum therapy Patients active infection Patients concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , hypertension , ischemic heart disease , congestive heart failure , etc . ) Patients history chronic active hepatitis cirrhosis Patients HIV Patients active central nervous system ( CNS ) metastasis . Patients know CNS metastasis must receive prior radiation therapy , CNS metastatic disease must stable 4 week . Patients recover acute effect prior antineoplastic therapy Patients know hypersensitivity platinum drug manage concomitant medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Recurrent Ovarian Epithelial Cancer</keyword>
	<keyword>Stage IV Ovarian Epithelial Cancer</keyword>
	<keyword>Peritoneal Cavity Cancer</keyword>
	<keyword>Stage III Ovarian Epithelial Cancer</keyword>
</DOC>